Fixed-combination intraocular pressure-lowering therapy for glaucoma and ocular hypertension: advantages in clinical practice

Bibliography

• Casson RJ, Chidlow G, Wood JP, et al. Definition of glaucoma: clinical and experimental concepts. Clin Experiment Ophthalmol 2012;40:341-9
   PubMed Web of Science ®Google Scholar
• Quigley HA, Broman AT. The number of people with glaucoma worldwide in. 2010 and 2020. Br J Ophthalmol 2006;90:262-7
   PubMed Web of Science ®Google Scholar
• Miglior S, Pfeiffer N, Torri V, et al. Predictive factors for open-angle glaucoma among patients with ocular hypertension in the european glaucoma prevention study. Ophthalmology 2007;114:3-9
   PubMed Web of Science ®Google Scholar
• Kass MA, Heuer DK, Higginbotham EJ, et al. The ocular hypertension treatment study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002;120:701-13
   PubMed Web of Science ®Google Scholar
• Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: results from the early manifest glaucoma trial. Arch Ophthalmol 2002;120:1268-79
   PubMed Web of Science ®Google Scholar
• Bengtsson B, Leske MC, Hyman L, et al. Fluctuation of intraocular pressure and glaucoma progression in the early manifest glaucoma trial. Ophthalmology 2007;114:205-9
   PubMed Web of Science ®Google Scholar
• Fukuchi T, Yoshino T, Sawada H, et al. The relationship between the mean deviation slope and follow-up intraocular pressure in open-angle glaucoma patients. J Glaucoma 2013;22:689-97
   PubMedGoogle Scholar
• McKean-Cowdin R, Wang Y, Wu J, et al. Impact of visual field loss on health-related quality of life in glaucoma: the los angeles latino eye study. Ophthalmology 2008;115:941-8
   PubMed Web of Science ®Google Scholar
• Jampel HD, Frick KD, Janz NK, et al. Depression and mood indicators in newly diagnosed glaucoma patients. Am J Ophthalmol 2007;144:238-44
   PubMed Web of Science ®Google Scholar
• Peters D, Bengtsson B, Heijl A. Factors associated with lifetime risk of open-angle glaucoma blindness. Acta Ophthalmol 2013; doi: 10.1111/aos.12203
   PubMed Web of Science ®Google Scholar
• Stewart WC, Kolker AE, Sharpe ED, et al. Long-term progression at individual mean intraocular pressure levels in primary open-angle and exfoliative glaucoma. Eur J Ophthalmol 2008;18:765-70
   PubMed Web of Science ®Google Scholar
• The AGIS investigators. The advanced glaucoma intervention study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 2000;130:429-40
   PubMed Web of Science ®Google Scholar
• Miglior S, Zeyen T, Pfeiffer N, et al. Results of the european glaucoma prevention study. Ophthalmology 2005;112:366-75
   PubMed Web of Science ®Google Scholar
• Lichter PR, Musch DC, Gillespie BW, et al. Interim clinical outcomes in the collaborative initial glaucoma treatment study comparing initial treatment randomized to medications or surgery. Ophthalmology 2001;108:1943-53
   PubMed Web of Science ®Google Scholar
• Collaborative normal-tension glaucoma study group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol 1998;126:487-97
   PubMed Web of Science ®Google Scholar
• Collaborative normal-tension glaucoma study group. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Ophthalmol 1998;126:498-505
   PubMed Web of Science ®Google Scholar
• van Gestel A, Webers CA, Severens JL, et al. The long-term outcomes of four alternative treatment strategies for primary open-angle glaucoma. Acta Ophthalmol 2012;90:20-31
   PubMed Web of Science ®Google Scholar
• Webers CA, Beckers HJ, Nuijts RM, Schouten JS. Pharmacological management of primary open-angle glaucoma: second-line options and beyond. Drugs Aging 2008;25:729-59
   PubMed Web of Science ®Google Scholar
• Leske MC, Heijl A, Hussein M, et al. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol 2003;121:48-56
   PubMed Web of Science ®Google Scholar
• Quaranta L, Katsanos A, Russo A, Riva I. 24-hour intraocular pressure and ocular perfusion pressure in glaucoma. Surv Ophthalmol 2013;58:26-41
   PubMed Web of Science ®Google Scholar
• Konstas AG, Hollo G, Haidich AB, et al. Comparison of 24-hour intraocular pressure reduction obtained with brinzolamide/timolol or brimonidine/timolol fixed-combination adjunctive to travoprost therapy. J Ocul Pharmacol Ther 2013;29:652-7
   PubMed Web of Science ®Google Scholar
• Konstas AG, Quaranta L, Realini T. Overview of the [corrected] travoprost/timolol BAK-free fixed combination. Expert Opin Pharmacother 2012;13:757-66
   PubMed Web of Science ®Google Scholar
• Barkana Y, Anis S, Liebmann J, et al. Clinical utility of intraocular pressure monitoring outside of normal office hours in patients with glaucoma. Arch Ophthalmol 2006;124:793-7
   PubMed Web of Science ®Google Scholar
• Caprioli J, Coleman AL. Intraocular pressure fluctuation a risk factor for visual field progression at low intraocular pressures in the advanced glaucoma intervention study. Ophthalmology 2008;115:1123-9. e3
   PubMed Web of Science ®Google Scholar
• Schacknow PN, Samples JR. Medications used to treat glaucoma. In: Schacknow PN, Samples JR, editors. The glaucoma book. Springer; New York: 2010. p. 583-628
   Google Scholar
• McCarty CA, Mukesh BN, Kitchner TE, et al. Intraocular pressure response to medication in a clinical setting: the marshfield clinic personalized medicine research project. J Glaucoma 2008;17:372-7
   PubMedGoogle Scholar
• Kobelt-Nguyen G, Gerdtham UG, Alm A. Costs of treating primary open-angle glaucoma and ocular hypertension: a retrospective, observational two-year chart review of newly diagnosed patients in Sweden and the United States. J Glaucoma 1998;7:95-104
   PubMed Web of Science ®Google Scholar
• Boyle JE, Ghosh K, Gieser DK, Adamsons IA. A randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzolamide. Dorzolamide-Timolol Study Group. Ophthalmology 1998;105:1945-51
   PubMed Web of Science ®Google Scholar
• Brandt JD, Cantor LB, Katz LJ, et al. Bimatoprost/timolol fixed combination: a 3-month double-masked, randomized parallel comparison to its individual components in patients with glaucoma or ocular hypertension. J Glaucoma 2008;17:211-16
   PubMed Web of Science ®Google Scholar
• Higginbotham EJ, Olander KW, Kim EE, et al. Fixed combination of latanoprost and timolol vs individual components for primary open-angle glaucoma or ocular hypertension: a randomized, double-masked study. Arch Ophthalmol 2010;128:165-72
   PubMed Web of Science ®Google Scholar
• Kaback M, Scoper SV, Arzeno G, et al. Intraocular pressure-lowering efficacy of brinzolamide 1%/timolol 0.5% fixed combination compared with brinzolamide 1% and timolol 0.5%. Ophthalmology 2008;115:1728-34
   PubMed Web of Science ®Google Scholar
• Sherwood MB, Craven ER, Chou C, et al. Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial. Arch Ophthalmol 2006;124:1230-8
   PubMed Web of Science ®Google Scholar
• Aptel F, Cucherat M, Denis P. Efficacy and tolerability of prostaglandin-timolol fixed combinations: a meta-analysis of randomized clinical trials. Eur J Ophthalmol 2012;22:5-18
   PubMed Web of Science ®Google Scholar
• Diestelhorst M, Larsson LI. European-canadian latanoprost fixed combination study group. A 12-week, randomized, double-masked, multicenter study of the fixed combination of latanoprost and timolol in the evening versus the individual components. Ophthalmology 2006;113:70-6
   PubMed Web of Science ®Google Scholar
• Inoue K, Shiokawa M, Sugahara M, et al. Three-month evaluation of dorzolamide hydrochloride/timolol maleate fixed-combination eye drops versus the separate use of both drugs. Jpn J Ophthalmol 2012;56:559-63
   PubMedGoogle Scholar
• Zhao JL, Ge J, Li XX, et al. Comparative efficacy and safety of the fixed versus unfixed combination of latanoprost and timolol in Chinese patients with open-angle glaucoma or ocular hypertension. BMC Ophthalmol 2011;11:23
   PubMedGoogle Scholar
• Choudhri S, Wand M, Shields MB. A comparison of dorzolamide-timolol combination versus the concomitant drugs. Am J Ophthalmol 2000;130:832-3
   PubMed Web of Science ®Google Scholar
• Strohmaier K, Snyder E, DuBiner H, Adamsons I. The efficacy and safety of the dorzolamide-timolol combination versus the concomitant administration of its components. Dorzolamide-timolol study group. Ophthalmology 1998;105:1936-44
   PubMed Web of Science ®Google Scholar
• Quaranta L, Biagioli E, Riva I, et al. Prostaglandin analogs and timolol-fixed versus unfixed combinations or monotherapy for open-angle glaucoma: a systematic review and meta-analysis. J Ocul Pharmacol Ther 2012;29:382-9
   PubMedGoogle Scholar
• Bagga H, Liu JH, Weinreb RN. Intraocular pressure measurements throughout the 24 h. Curr Opin Ophthalmol 2009;20:79-83
   PubMed Web of Science ®Google Scholar
• Liu JH, Realini T, Weinreb RN. Asymmetry of 24-hour intraocular pressure reduction by topical ocular hypotensive medications in fellow eyes. Ophthalmology 2011;118:1995-2000
   PubMedGoogle Scholar
• Tanaka S, Watanabe M, Inatomi S, et al. Effects of several anti-glaucoma medications on the circadian intraocular pressure fluctuations in patients with primary open-angle glaucoma. J Ocul Pharmacol Ther 2014;30:12-20
   PubMedGoogle Scholar
• Konstas AG, Mikropoulos D, Kaltsos K, et al. 24-hour intraocular pressure control obtained with evening- versus morning-dosed travoprost in primary open-angle glaucoma. Ophthalmology 2006;113:446-50
   PubMed Web of Science ®Google Scholar
• Alm A, Stjernschantz J. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group. Ophthalmology 1995;102:1743-52
   PubMed Web of Science ®Google Scholar
• Konstas AG, Nakos E, Tersis I, et al. A comparison of once-daily morning vs evening dosing of concomitant latanoprost/timolol. Am J Ophthalmol 2002;133:753-7
   PubMed Web of Science ®Google Scholar
• Okeke CO, Quigley HA, Jampel HD, et al. Adherence with topical glaucoma medication monitored electronically: the travatan dosing aid study. Ophthalmology 2009;116:191-9
   PubMed Web of Science ®Google Scholar
• Rossi GC, Pasinetti GM, Scudeller L, et al. Monitoring adherence rates in glaucoma patients using the Travatan Dosing Aid. A 6-month study comparing patients on travoprost 0.004% and patients on travoprost 0.004%/timolol 0.5% fixed combination. Expert Opin Pharmacother 2010;11:499-504
   PubMed Web of Science ®Google Scholar
• Andrade S. Compliance in the real world. Value Health 1998;1:171-3
   PubMedGoogle Scholar
• Robin AL, Covert D. Does adjunctive glaucoma therapy affect adherence to the initial primary therapy? Ophthalmology 2005;112:863-8
   PubMed Web of Science ®Google Scholar
• Robin AL, Novack GD, Covert DW, et al. Adherence in glaucoma: objective measurements of once-daily and adjunctive medication use. Am J Ophthalmol 2007;144:533-40
   PubMed Web of Science ®Google Scholar
• Sleath B, Robin AL, Covert D, et al. Patient-reported behavior and problems in using glaucoma medications. Ophthalmology 2006;113:431-6
   PubMed Web of Science ®Google Scholar
• Rossi GC, Pasinetti GM, Scudeller L, et al. Do adherence rates and glaucomatous visual field progression correlate? Eur J Ophthalmol 2011;21:410-14
   PubMed Web of Science ®Google Scholar
• Reardon G, Kotak S, Schwartz GF. Objective assessment of compliance and persistence among patients treated for glaucoma and ocular hypertension: a systematic review. Patient Prefer Adherence 2011;5:441-63
   PubMed Web of Science ®Google Scholar
• Djafari F, Lesk MR, Harasymowycz PJ, et al. Determinants of adherence to glaucoma medical therapy in a long-term patient population. J Glaucoma 2009;18:238-43
   PubMed Web of Science ®Google Scholar
• Friedman DS, Okeke CO, Jampel HD, et al. Risk factors for poor adherence to eyedrops in electronically monitored patients with glaucoma. Ophthalmology 2009;116:1097-105
   PubMed Web of Science ®Google Scholar
• Taylor SA, Galbraith SM, Mills RP. Causes of non-compliance with drug regimens in glaucoma patients: a qualitative study. J Ocul Pharmacol Ther 2002;18:401-9
   PubMed Web of Science ®Google Scholar
• Vorwerk C, Thelen U, Buchholz P, Kimmich F. Treatment of glaucoma patients with insufficient intraocular pressure control: a survey of German ophthalmologists in private practice. Curr Med Res Opin 2008;24:1295-301
   PubMed Web of Science ®Google Scholar
• Tsai JC, McClure CA, Ramos SE, et al. Compliance barriers in glaucoma: a systematic classification. J Glaucoma 2003;12:393-8
   PubMed Web of Science ®Google Scholar
• Gurwitz JH, Glynn RJ, Monane M, et al. Treatment for glaucoma: adherence by the elderly. Am J Public Health 1993;83:711-16
   PubMed Web of Science ®Google Scholar
• Rotchford AP, Murphy KM. Compliance with timolol treatment in glaucoma. Eye (Lond) 1998;12:234-6
   PubMed Web of Science ®Google Scholar
• Kashiwagi K, Furuya T. Persistence with topical glaucoma therapy among newly diagnosed Japanese patients. Jpn J Ophthalmol 2014;58:68-74
   PubMed Web of Science ®Google Scholar
• Schwartz G, Burk C, Bennett T, Patel VD. Adherence and persistence with glaucoma therapy: brimonidine/timolol versus dorzolamide/timolol and various two-bottle combinations. J Clin Exp Ophthalmol 2012;3:1-6
   Google Scholar
• Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007;120:713-19
   PubMed Web of Science ®Google Scholar
• Chrai SS, Makoid MC, Eriksen SP, Robinson JR. Drop size and initial dosing frequency problems of topically applied ophthalmic drugs. J Pharm Sci 1974;63:333-8
   PubMed Web of Science ®Google Scholar
• Urtti A. Challenges and obstacles of ocular pharmacokinetics and drug delivery. Adv Drug Deliv Rev 2006;58:1131-5
   PubMed Web of Science ®Google Scholar
• Buller A, Hercules BL. Should patients choose their own eyedrops? Acta Ophthalmol Scand 2006;84:150-1
   PubMedGoogle Scholar
• Lee MD, Fechtner FR, Fiscella RG, et al. Emerging perspectives on glaucoma: highlights of a roundtable discussion. Am J Ophthalmol 2000;130:S1-11
   PubMedGoogle Scholar
• Fechtner RD, Godfrey DG, Budenz D, et al. Prevalence of ocular surface complaints in patients with glaucoma using topical intraocular pressure-lowering medications. Cornea 2010;29:618-21
   PubMed Web of Science ®Google Scholar
• Rossi GC, Pasinetti GM, Scudeller L, Bianchi PE. Ocular surface disease and glaucoma: how to evaluate impact on quality of life. J Ocul Pharmacol Ther 2013;29:390-4
   PubMed Web of Science ®Google Scholar
• Leung EW, Medeiros FA, Weinreb RN. Prevalence of ocular surface disease in glaucoma patients. J Glaucoma 2008;17:350-5
   PubMed Web of Science ®Google Scholar
• Skalicky SE, Goldberg I, McCluskey P. Ocular surface disease and quality of life in patients with glaucoma. Am J Ophthalmol 2012;153:1-9. e2
   PubMed Web of Science ®Google Scholar
• Rossi GC, Pasinetti GM, Scudeller L, et al. Risk factors to develop ocular surface disease in treated glaucoma or ocular hypertension patients. Eur J Ophthalmol 2013;23:296-302
   PubMed Web of Science ®Google Scholar
• Januleviciene I, Derkac I, Grybauskiene L, et al. Effects of preservative-free tafluprost on tear film osmolarity, tolerability, and intraocular pressure in previously treated patients with open-angle glaucoma. Clin Ophthalmol 2012;6:103-9
   PubMedGoogle Scholar
• Baudouin C, Labbe A, Liang H, et al. Preservatives in eyedrops: the good, the bad and the ugly. Prog Retin Eye Res 2010;29:312-34
   PubMed Web of Science ®Google Scholar
• Tomic M, Kastelan S, Metez Soldo K, Salopek-Rabatic J. Influence of BAK-preserved prostaglandin analog treatment on the ocular surface health in patients with newly diagnosed primary open-angle glaucoma. Biomed Res Int 2013; doi: 10.1155/2013/603782
   Google Scholar
• Liang H, Brignole-Baudouin F, Pauly A, et al. Polyquad-preserved travoprost/timolol, benzalkonium chloride (BAK)-preserved travoprost/timolol, and latanoprost/timolol in fixed combinations: a rabbit ocular surface study. Adv Ther 2011;28:311-25
   PubMed Web of Science ®Google Scholar
• Ammar DA, Kahook MY. Effects of benzalkonium chloride- or polyquad-preserved fixed combination glaucoma medications on human trabecular meshwork cells. Mol Vis 2011;17:1806-13
   PubMed Web of Science ®Google Scholar
• Ammar DA, Noecker RJ, Kahook MY. Effects of benzalkonium chloride- and polyquad-preserved combination glaucoma medications on cultured human ocular surface cells. Adv Ther 2011;28:501-10
   PubMed Web of Science ®Google Scholar
• Boimer C, Birt CM. Preservative exposure and surgical outcomes in glaucoma patients: the PESO study. J Glaucoma 2013;22:730-5
   PubMed Web of Science ®Google Scholar
• Costagliola C, Prete AD, Incorvaia C, et al. Ocular surface changes induced by topical application of latanoprost and timolol: a short-term study in glaucomatous patients with and without allergic conjunctivitis. Graefes Arch Clin Exp Ophthalmol 2001;239:809-14
   PubMed Web of Science ®Google Scholar
• Kitazawa Y, Smith P, Sasaki N, et al. Travoprost 0.004%/timolol 0.5%-fixed combination with and without benzalkonium chloride: a prospective, randomized, doubled-masked comparison of safety and efficacy. Eye (Lond) 2011;25:1161-9
   PubMed Web of Science ®Google Scholar
• Lewis RA, Katz GJ, Weiss MJ, et al. Travoprost 0.004% with and without benzalkonium chloride: a comparison of safety and efficacy. J Glaucoma 2007;16:98-103
   PubMed Web of Science ®Google Scholar
• Gandolfi S, Paredes T, Goldberg I, et al. Comparison of a travoprost BAK-free formulation preserved with polyquaternium-1 with BAK-preserved travoprost in ocular hypertension or open-angle glaucoma. Eur J Ophthalmol 2012;22:34-44
   PubMed Web of Science ®Google Scholar
• Shedden A, Adamsons IA, Getson AJ, et al. Comparison of the efficacy and tolerability of preservative-free and preservative-containing formulations of the dorzolamide/timolol fixed combination (COSOPT) in patients with elevated intraocular pressure in a randomized clinical trial. Graefes Arch Clin Exp Ophthalmol 2010;248:1757-64
   PubMed Web of Science ®Google Scholar
• Whitson JT, Ochsner KI, Moster MR, et al. The safety and intraocular pressure-lowering efficacy of brimonidine tartrate 0.15% preserved with polyquaternium-1. Ophthalmology 2006;113:1333-9
   PubMed Web of Science ®Google Scholar
• Easty DL, Nemeth-Wasmer G, Vounatsos JP, et al. Comparison of a non-preserved 0.1% T-Gel eye gel (single dose unit) with a preserved 0.1% T-Gel eye gel (multidose) in ocular hypertension and glaucomatous patients. Br J Ophthalmol 2006;90:574-8
   PubMed Web of Science ®Google Scholar
• Day DG, Walters TR, Schwartz GF, et al. Bimatoprost 0.03% preservative-free ophthalmic solution versus bimatoprost 0.03% ophthalmic solution (Lumigan) for glaucoma or ocular hypertension: a 12-week, randomised, double-masked trial. Br J Ophthalmol 2013;97:989-93
   PubMed Web of Science ®Google Scholar
• Holló G, Hommer A, Anton López A, Ropo A. Efficacy, safety, and tolerability of preservative-free fixed combination of tafluprost 0.0015%/timolol 0.5% versus concomitant use of the ingredients. J Ocul Pharmacol Ther 2014;30(6):468-75
   PubMed Web of Science ®Google Scholar
• Goldberg I, Gil Pina R, Lanzagorta-Aresti A, et al. Bimatoprost 0.03%/timolol 0.5% preservative-free ophthalmic solution versus bimatoprost 0.03%/timolol 0.5% ophthalmic solution (Ganfort) for glaucoma or ocular hypertension: a 12-week randomised controlled trial. Br J Ophthalmol 2014;98(7):926-31
   PubMedGoogle Scholar
• Jaenen N, Baudouin C, Pouliquen P, et al. Ocular symptoms and signs with preserved and preservative-free glaucoma medications. Eur J Ophthalmol 2007;17:341-9
   PubMed Web of Science ®Google Scholar
• Pisella PJ, Pouliquen P, Baudouin C. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br J Ophthalmol 2002;86:418-23
   PubMed Web of Science ®Google Scholar
• Khouri AS, Realini T, Fechtner RD. Use of fixed-dose combination drugs for the treatment of glaucoma. Drugs Aging 2007;24:1007-16
   PubMed Web of Science ®Google Scholar
• Hommer A, Thygesen J, Ferreras A, et al. A European perspective on costs and cost effectiveness of ophthalmic combinations in the treatment of open-angle glaucoma. Eur J Ophthalmol 2008;18:778-86
   PubMed Web of Science ®Google Scholar
• Higginbotham EJ. Considerations in glaucoma therapy: fixed combinations versus their component medications. Clin Ophthalmol 2010;4:1-9
   PubMedGoogle Scholar
• American Academy of Ophthalmology Glaucoma panel. Preferred practice pattern® guidelines. Primary open-angle glaucoma. American Academy of Ophthalmology; San Francisco, CA: 2010
   Google Scholar
• European Glaucoma Society. Terminology and guidelines for glaucoma. 3rd edtion. Dogma S.r.l; Savona, Italy: 2008
   Google Scholar
• National Institute of Clinical Excellence. Glaucoma: diagnosis and management of chronic open angle glaucoma and ocular hypertension. Available from: http://guidance.nice.org.uk/CG85/Guidance/pdf/English [Last accessed 16 January 2014]
   Google Scholar
• Stewart WC, Kruft B, Nelson LA, Stewart JA. Ophthalmologist attitudes regarding fixed combination treatment for glaucoma in the European Union. Eur J Ophthalmol 2009;19:588-93
   PubMed Web of Science ®Google Scholar
• Hollo G, Kothy P. Intraocular pressure reduction with travoprost/timolol fixed combination, with and without adjunctive brinzolamide, in glaucoma. Curr Med Res Opin 2008;24:1755-61
   PubMed Web of Science ®Google Scholar
• Akman A, Cetinkaya A, Akova YA, Ertan A. Comparison of additional intraocular pressure-lowering effects of latanoprost vs brimonidine in primary open-angle glaucoma patients with intraocular pressure uncontrolled by timolol-dorzolamide combination. Eye (Lond) 2005;19:145-51
   PubMed Web of Science ®Google Scholar